VICO Therapeutics B.V.

Exciting moment for VICO to present our first clinical data with VO659 in Huntington's Disease patients today at the European Huntington's Disease Network conference!

Today at the European Huntington's Disease Network (EHDN)’s EHDN & Enroll-HD 2024 meeting, we announced new interim data from our ongoing Phase 1/2a clinical study, including a safety, tolerability, and biomarker analysis for participants with Huntington’s disease. This study is part of our broader research into therapies targeting diseases caused by CAG repeat expansions, and we look forward to advancing the program and discussing future steps with regulators later this year. See our press release for more information: https://lnkd.in/e9hxmhV5 #EHDN2024 #EnrollHD2024 #HuntingtonsDisease #SpinocerebellarAtaxia #Neurology #ClinicalResearch #NeurodegenerativeDiseases #ClinicalTrials

We’re excited to attend LSX World Congress USA in Boston from September 11-12, where our CEO, Micah Mackison, will engage in one-on-one investor meetings. Looking forward to connecting with industry leaders and advancing our mission to treat genetic neurological diseases at the source. #LSXUSA Find more information at https://lnkd.in/ewdUeYr9

We’re looking forward to the European Huntington's Disease Network (EHDN)’s EHDN & Enroll-HD 2024 meeting, taking place September 12-14 in Strasbourg, France. On Friday, September 13th at 9:45 CET, Dr. Scott Schobel, our Chief Medical Officer, will present an update from our ongoing Phase 1/2a clinical study in Huntington’s disease. This event offers a valuable opportunity to share our latest clinical insights and engage with the global community dedicated to advancing care for challenging neurological conditions. #EHDN2024 #EnrollHD2024 #HuntingtonsDisease #SpinocerebellarAtaxia #Neurology #ClinicalResearch #NeurodegenerativeDiseases #ClinicalTrials

Join us in supporting the EHDN's mission to advance Huntington's disease research. We support their commitment to facilitating knowledge through various initiatives including open data sharing, clinical trial support, funding opportunities and educational programs. Two major international observational studies, Enroll-HD and Registry, are conducted at EHDN study sites, providing valuable clinical data and biosamples for researchers worldwide. Learn more about their work at https://ehdn.org/ #EHDN #HuntingtonsDisease #HDCommunity

Last month the Huntington’s Disease Society of America celebrated 32 years of Huntington’s Disease Awareness Month with a series of events across the country and an online initiative called #letstalkabouthd. This campaign seeks to raise awareness and support for those affected by Huntington’s disease (HD), culminating in the HDSA Annual Convention, the largest gathering of HD families in the world, to be held in Spokane, WA. It was a privilege to join with HD advocates and families and listen and learn from their experiences. Learn more about their efforts: https://hdsa.org/

This recent study marks a significant advancement in #HuntingtonsDisease (HD) research by detecting and quantifying mutant huntingtin (mHTT) levels in tear fluid, providing a non-invasive alternative to invasive CSF sampling. This breakthrough offers a promising alternative for cost-effective and participant-friendly disease monitoring and future therapeutic trials. Additionally, the potential of tear fluid biomarkers extends beyond HD, showing promise for neurological and neurodegenerative disease research. We are proud to contribute to the advancement of new biomarker analysis options for the benefit of the Huntington’s disease community: https://lnkd.in/exTd4Dzq

Reminder! Our team is in San Diego to explore partnering and strategic opportunities for our pipeline of innovative #RNA modulating therapies for genetic neurological diseases, including polyglutamine diseases spinocerebellar ataxia types 3 and 1 (SCA3, SCA1) and #Huntingtonsdisease (HD). Connect with us through BIO’s 1x1 Partnering Platform: https://lnkd.in/gm_2Vp4G

Attending #BIO2024? Our Chief Executive Officer Micah Mackison and Chief Medical Officer Scott Schobel are in San Diego to explore partnering and strategic opportunities for our pipeline of innovative #RNA modulating therapies for genetic neurological diseases, including polyglutamine diseases spinocerebellar ataxia types 3 and 1 (SCA3, SCA1) and #Huntingtonsdisease (HD). Connect with us through BIO’s 1x1 Partnering Platform: https://lnkd.in/gm_2Vp4G

Our team is in Orlando for this year’s Annual Ataxia Conference: Partnering for Progress, where we look forward to connecting with individuals living with spinocerebellar ataxia type 3 and type 1. Thank you to the ACC for bringing this impactful program to the #Ataxia community. Learn more about their efforts at https://lnkd.in/eCnS4ju2